BERLIN (Reuters) – EQT’s Galderma on Wednesday said its injectable drug nemolizumab helped patients suffering from the rare skin disease prurigo nodularis in a trial, potentially underpinning the owner’s ambitions to list the skincare firm.
In a late-stage trial, Galderma’s drug was shown to remove lesions and ease itch in some patients. Itch is a chronic symptom of the potentially debilitating skin disease.
Sources told Reuters in May that EQT is delaying listing plans for Galderma as market volatility and recession fears in Europe cool investor appetite for what could be Switzerland’s biggest flotation in more than two decades.
The listing could happen in the autumn or early next year depending on market conditions, the sources said at the time.
Japan’s Maruho Co. Ltd is also working on a prurigo nodularis treatment while French drugmaker Sanofi is running trials to get its bestselling eczema drug Dupixent also approved for the disease.
(Reporting by Ludwig Burger, Writing by Miranda Murray)
